Walk into a hospital pharmacy on Monday morning and ask for a vial of Samtepa, a chemotherapy injection. Last week, the price printed on the pack was Rs 80,071.86. From 9 November, the same vial costs Rs 7,150.33. That is not a festival discount or a hospital offer. It is the new maximum retail price, fixed by the drug price regulator, and it is the sharpest edge of a change in cancer drug prices that reaches more than a thousand formulations across India.
The story began a month ago, when the National Pharmaceutical Pricing Authority approved a cap on trade margins for identified anti-cancer drugs in principle. Read how the cap was first approved Since then, an expert committee named 137 drugs, the NPPA issued its order on 17 October, and drug companies spent three weeks filing revised prices. Now the list is published, the new prices are public, and they take effect on Monday, 9 November.
What cancer drug prices look like from Monday
The scale is what makes this different from an ordinary price notification. According to the Ministry of Chemicals and Fertilizers, 76 companies have reported revised prices for 1,031 formulations covering 121 drugs. Around 600 brands have been cut by more than half. The biggest single reduction reported so far is 96.45%. The government puts the annual saving for patients at Rs 3,502.31 crore.
The individual examples are hard to read without pausing. Samtepa, a 100 mg vial, falls from Rs 80,071.86 to Rs 7,150.33, a cut of about 91%. Palbopro, a breast cancer medicine containing palbociclib, drops from Rs 40,421.33 to Rs 2,720 for 21 capsules of 125 mg each. Hertumab, used in some breast cancers, falls from Rs 94,951 to Rs 30,593 a vial. Then there is the other side of the list. Keytruda, the immunotherapy pembrolizumab, stays exactly where it was, at Rs 216,000 for a 100 mg vial. The cap squeezes the middleman, not the manufacturer, and where the manufacturer’s own price is the problem, nothing changes.
Why the middle of the chain was the problem
A trade margin is the gap between what a manufacturer charges a distributor and the maximum retail price printed on the pack. Distributors, wholesalers, retailers and hospital pharmacies all take their cut inside that gap, and on some cancer drugs the gap had grown enormous. The NPPA’s order caps that margin at 30% of the MRP, excluding GST, and works the new prices back from the average distributor price of March 2026. The cap covers all 137 drugs in every strength, form and combination, including patented and imported medicines. Ten to fifteen of the listed drugs have not launched in India yet, and the cap will apply to them when they do.
Two numbers in the announcement deserve a second look. The Rs 3,502 crore saving is a projection, worked out by applying the new prices to the quantities sold between April 2025 and March 2026. It is not money patients have already saved. And a 30% cap is not a 30% discount on every drug. The size of the cut depends entirely on how fat the margin was, which is why one vial falls 91% and another does not move at all.
The catch nobody should miss
Only the 137 listed drugs are covered, so most of what a cancer patient pays for, from consultations and scans to hospital stays, is untouched by this order. And where treatment is sold as a package rather than item by item, margins have a habit of migrating into other lines of the bill. October has been a busy month for economic policy in Delhi: alongside the drug price order, the GST Council stripped tax officers of arrest powers and raised the prosecution threshold five-fold. Announcements are easy. The test, as always, is the bill.
How to check your medicine’s price
Patients can check the revised price of a specific medicine on the NPPA website or the Pharma Sahi Daam app, under the section marked TMR, Cancer Drugs (Revised Prices of Anti-Cancer Drugs). Pharmacies and hospitals are required to charge the revised MRP from 9 November, and a medicine already priced below the new limit cannot be made more expensive. If the price on the pack or the bill does not match the published list, that mismatch is worth questioning on the spot.
Monday will tell us whether the number on the bill actually changes. If you or someone in your family buys one of these medicines, check the MRP on the pack before you pay, and ask the pharmacist to show you the revised price. A cap announced in Delhi only becomes relief when it survives the walk to the pharmacy counter.